Background

Aubrai is presented as a decentralized scientific agent focused on longevity research. It is co-developed by VitaDAO and BIO to support hypothesis generation, validation, and experiment planning in high-complexity aging biology programs.

RMR2 Objective

The RMR2 target is robust mouse rejuvenation: identify an intervention program that materially extends remaining lifespan in wild-type adult mice by combining therapies across multiple aging hallmarks rather than relying on single-pathway effects.

Study Design Highlights

• Interventions begin in mid-late life (about 18 to 20 months).
• The protocol plans 10 treatment groups to evaluate both single interventions and higher-order interaction effects.
• Primary endpoint focuses on treatment-group interaction effects on overall lifespan, with secondary tracking of morbidity trajectories, causes of death, and functional decline.
• Control design includes both mock and naive controls to separate administration/vehicle effects from active treatment effects.
• Scale target is approximately 500 male and 500 female mice to preserve statistical power in a multiplexed design.

Intervention Selection Framework

RMR2 selection criteria prioritize evidence of damage-reversal potential, mechanistic divergence across interventions, durability of benefit, translatability, technical feasibility at large scale, and financial practicality.

Top-Line Intervention Set in RMR2 Docs

• Deuterated fatty acids (D-PUFAs)
• Mouse serum albumin (rMSA)
• Mesenchymal stem cells or exosome-oriented alternatives
• Partial cellular reprogramming
• Anti-IL-11
• CDC42 inhibition (CASIN)
• Senolysis (Rockfish track)
• Oxytocin therapy

Docs also describe interaction hypotheses (for example D-PUFAs with senolytic and mTOR-pathway contexts) and baseline context choices such as broad rapamycin exposure and voluntary wheel access to reduce inactivity confounding.